SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains on receiving USFDA approval for Generic Ambien CR Extended-release tablets

17 Sep 2013 Evaluate

Lupin is currently trading at Rs. 841.65, up by 3.25 points or 0.39% from its previous closing of Rs. 838.40 on the BSE.

The scrip opened at Rs. 840.20 and has touched a high and low of Rs. 844.55 and Rs. 839.00 respectively. So far 5,535 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 908.00 on 19-Jul-2013 and a 52 week low of Rs. 540.15 on 11-Oct-2012.

Last one week high and low of the scrip stood at Rs. 880.00 and Rs. 827.00 respectively. The current market cap of the company is Rs. 37,697.00 crore.

The promoters holding in the company stood at 46.81% while Institutions and Non-Institutions held 43.07% and 10.12% respectively.

Lupin has received final approval for its Zolpidem Tartrate Extended?release tablets USP, 6.25 mg and 12.5 mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Sanofi Aventis, US, LLC’s (Sanofi) Ambien CR Extended?release tablets, 6.25 mg and 12.5 mg. The company’s wholly owned US subsidiary Lupin Pharmaceuticals Inc. (LPI) shall commence marketing the product shortly.

Lupin’s Zolpidem CR tablets 6.25 mg & 12.5 mg is the AB rated generic equivalent of Sanofi’s Ambien CR Extended?release tablets, 6.25 mg and 12.5 mg and is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Sanofi’s Ambien CR Extended?release tablets had annual US sales of approximately $366 million, as per IMS MAT March 2013.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×